APRINOIA Therapeutics

Focus: APRINOIA Therapeutics is a Hong Kong-based diagnostics and therapeutics company focused on Alzheimer's disease treatments and biomarker detection. Founded in 2024, the company is in very early stages with a lean pipeline in neurology.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About APRINOIA Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow APRINOIA Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

A Direct Comparative Study of Tau Tracer in Patients With Alzheimer's Disease

Alzheimer Disease

N/A

APNmAb005

Alzheimer's Disease

Phase 1

Clinical Trials (1)

Help build intelligence for APRINOIA Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Phase 3 asset ([18F]APN-1607) in high-unmet-need Alzheimer's space offers potential near-term clinical validation and regulatory pathway visibility
Ground-floor opportunity at 2024 startup to shape company culture, processes, and intellectual property from inception
Dual diagnostic-therapeutic approach addresses both detection and treatment in neurodegenerative disease, differentiating from single-modality competitors

Watch Out For

Zero public hiring activity despite two active clinical programs suggests severely constrained headcount or unfunded operations
No disclosed funding, revenue, or financial runway data creates high uncertainty about company viability and career stability
Extremely early stage (founded 2024) with skeleton team presents execution risk and limited mentorship/infrastructure for career development

Generated by Claude from APRINOIA Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT05344989A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Phase 1

[18F]APN-1607

Alzheimer's Disease

Phase 3

Clinical Trials (2)

NCT05542953[18F]APN-1607 PET in Subjects With AD Compared to HC

Phase 3

NCT04141150Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 3 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

3 pipeline

Marketed

Pipeline